Protocol Ledger

NCT07220083 · Phase III · RECRUITING

A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)

Interventional Phase III clinical trial protocol NCT07220083 sponsored by Boehringer Ingelheim in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-02-16 Enrollment: 286 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07220083
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)286 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07220083
Protocol FieldVerified Registry Value
NCT IdentifierNCT07220083
Consolidated Lead SponsorBoehringer Ingelheim
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment286 participants (ESTIMATED)
Registered Start Date2026-02-16
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07220083
Hospital Research SiteLocationSite Profile
Kaiser Permanente Los Angeles Medical CenterLos Angeles, CAOpen Hospital Dossier ->
UCLA Health and Jonsson Comprehensive Cancer CenterLos Angeles, CAOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Boehringer Ingelheim across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI